
Opinion|Videos|May 29, 2024
NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC
Author(s)Neal Shore, MD
Neal Shore, MD, FACS, describes the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC), and discusses the key efficacy results of pathologic complete response and major pathologic response rates.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- Describe the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in MIBC. What were the key efficacy results in terms of pathologic complete response and major pathologic response rates?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
2
Patients With CKD Are Less Likely to Receive Adjuvant Chemotherapy
3
Top 5 Most-Read Heart Failure Content of 2025
4
Overcoming Pain Points to Advance Bispecifics in the Community for Patients With Myeloma
5








































